Clinical Trials Logo

Malignancies clinical trials

View clinical trials related to Malignancies.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05929495 Not yet recruiting - Metformin Clinical Trials

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. The clinical trial will be single-arm to evaluate the biological activity and effects of metformin in combination with TMZ in patients with GBM.

NCT ID: NCT05602103 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Acute Cardiovascular Adverse Events Occuring in Children Treated by Anticancer Drugs for Malignancies

Start date: November 1, 2022
Phase:
Study type: Observational

Little is known about acute cardiovascular adverse events occuring in children treated by anticancer drugs for malignancies. Here the investigators use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database of individual safety case reports, to identify and describe cases of acute cardiovascular adverse events associated with anticancer drugs.